Top Five Health Care Venture Capital Deals Total $262.6 million In January 2007 (February 15, 2007)

Three biopharmas and two device makers comprise the top five health care venture deals, by dollar amount, announced during January 2007. Movetis, a biopharmaceutical company focused on gastrointestinal disorders, raised $63.4 million in Series A funding to complete development and filing of its lead Phase III compound, as well as to continue clinical development of three other products and move four additional products into preclinical and Phase I clinical development. Investors in Movetis this round include Sofinnova Partners, Life Sciences Ventures, KBC, GIMV, Quest for Growth and BIP Investment Partners. For the next deal, a $63.0 million Series C financing, Ception Therapeutics will use the proceeds continue preclinical and clinical development work on its late-stage biologic anti-inflammatory programs and other earlier- and discovery-stage programs. Ception is a biopharmaceutical company focused on therapeutic areas representing unmet medical needs. Essex Woodlands Health Ventures, Investor Growth Capital, MDS Capital, New Science Ventures, Aperture Venture Partners invested in Ception this round. Moving on, firms including Johnson & Johnson Development, Medtronic, Synergy Life Science Partners, Ascent Biomedical Ventures, Delphi Ventures and Frazier Healthcare Ventures recently invested in medical device company InnerPulse Technologies, which is targeting treatments for abnormal heart rhythms. InnerPulse is using the proceeds of the $50.0 million financing to complete the initial development of its implantable defibrillator and to support the infrastructure necessary to advance from early phase to human clinical trials and commercialization. Also noted, Cylene Pharmaceuticals, with its proprietary ribosomal RNA biosynthesis inhibition technology, is dedicated to the discovery, development and commercialization of small molecule drugs for treating life-threatening cancers. The proceeds from its recent $44.0 million Series C financing will be used to fund human clinical trials of its lead candidate in several different types of cancer. HBM BioVentures (Cayman) Ltd., Lilly Ventures, Sanderling Ventures, Novartis BioVenture Fund, BioVentures Investors, Research Corporation Technologies, Mitsui & Co. Venture Partners and Celgene Corporation are the investment firms that participated in this $44 million round for Cylene. Finally, in a $42.4 million Series D financing, provided by Apothecary Capital, Glenview Capital Management and Pequot Capital, Calypso Medical Technologies raised funding to accelerate the development of its technology, as well as for the commercial launch of its proprietary tumor localizaton and tracking system. Calypso’s system utilizes miniaturized implants to continuously pinpoint tumors for improved accuracy during radiation therapy.

Click here for a FREE TRIAL to the Healthcare Corporate Finance News

VC Blog Archive

Back to top